


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Withdrawn) A compound having the structure (I):



(I)

and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof, wherein

R¹ is selected from R⁵ and R⁵-(C₁-C₆ heteroalkylene)- where R⁵ is selected from hydrogen, halogen, alkyl, heteroalkyl, aryl, heteroaryl, carbocycle aliphatic ring and heterocycle aliphatic ring, amino or hydroxy;

R² and R³ are independently hydrogen, alkyl, heteroalkyl, aryl(alkylene), heteroaryl, heteroaryl(alkylene), carbocycle, carbocycle(alkylene), heterocycle, and heterocycle(alkylene);

each occurrence of R⁴ is independently selected from halogen, alkyl, heteroalkyl, aryl, heteroaryl, carbocycle aliphatic ring and heterocycle aliphatic ring, amino or hydroxy; and



n is 0, 1, 2 or 3.

2. (Withdrawn) A compound of claim 1 wherein n is 0.
3. (Withdrawn) A compound of claim 1 wherein n is 1.
4. (Withdrawn) A compound of claim 1 wherein n is 0 or 1 and R² is H.
5. (Withdrawn) A compound of claim 4 wherein R¹ is R⁵-SO₂- and R⁵ is selected from alkyl, heteroalkyl, aryl, carbocycle, aryl(alkylene), and carbocycle(alkylene).

6. (Withdrawn) A compound of claim 5 wherein, for R^5 , alkyl is C_1 - C_{10} alkyl; heteroalkyl is C_1 - C_{10} alkyl with 1, 2 or 3 heteroatoms selected from N, O and S; aryl is phenyl, substituted phenyl, naphthyl or substituted naphthyl; carbocycle is C_3 - C_8 carbocycle; and alkylene is C_1 - C_{10} alkylene.

7. (Withdrawn) A compound of claim 5 wherein R^1 is selected from $(C_1$ - C_6 alkyl) SO_2 , $PhSO_2$, fluorinatedphenyl SO_2 , $PhCH_2SO_2$, cyclopentyl SO_2 , *m*-carboxyphenyl SO_2 , *m*-methylphenyl SO_2 , and $HOOC$ -(C_1 - C_4 alkylene) SO_2 .

8. (Withdrawn) A compound of claim 1 wherein R^1 is selected from halogen, amino, hydrocarbylamino, dihydrocarbylamino, hydrocarbyloxy, hydrocarbylthio, heterocyclyl, (heteroalkyl)amino, and (heteroaryl)amino.

9. (Withdrawn) A compound of claim 7 wherein R^1 is selected from amino (C_1 - C_6 alkyl)(C_1 - C_6 alkyl)amino, $PhNH$ -, $PhCH_2NH$ -, , , and $HOCH_2CH_2NH$ -.


10. (Withdrawn) A compound of claim 8 wherein R^1 is selected from halide and $(C_1$ - C_6 alkyl) S -.

11. (Withdrawn) A compound of claim 10 wherein R^1 is chloride.

12. (Withdrawn) A compound of claim 4 wherein R^3 is selected from aryl, aryl(alkylene), heteroaryl, and heteroaryl(alkylene).

13. (Withdrawn) A compound of claim 12 wherein R^3 is aryl.

14. (Withdrawn) A compound of claim 1 having structure (II)



(II).

15. (Withdrawn) A compound of claim 14 wherein R^1 is selected from $(C_1$ - C_6 alkyl) SO_2 , $PhSO_2$, fluorinatedphenyl SO_2 , $PhCH_2SO_2$, cyclopentyl SO_2 , *m*-carboxyphenyl SO_2 , *m*-methylphenyl SO_2 , and $HOOC$ -(C_1 - C_4 alkylene) SO_2 .

16. (Withdrawn) A compound of claim 4 wherein R³ is benzyl or phenyl, the benzyl or phenyl having 0, 1, 2, 3 or 4 substituents selected from alkoxy, alkoxycarbonyl, alkyl, alkylamido, alkylcarbonyl, amido, benzyl optionally substituted, with halogen, benzyloxy, carboxy, cyano, dialkylamido, haloalkyl, haloalkyloxy, halogen, hydroxy, nitro, oxoalkyl, phenyl optionally substituted with halogen, thioalkyl, thiocyanate, and thiohaloalkyl.

17. (Withdrawn) A compound of claim 1 wherein R³ is selected from cycloalkyl, cycloalkyl(alkylene), cycloalkyl(heteroalkylene), heterocycloalkyl, heterocycloalkyl(alkylene), heterocydoalkyl(heteroalkylene), heteroaryl, heteroaryl(alkylene), and heteroaryl(heteroalkylene).

18. (Withdrawn) A compound of claim 1 wherein said compound is 6-Chloro-N-(4-fluoro-phenyl)-1-oxy-nicotinamide.

19. (Withdrawn) A compound of claim 1 wherein said compound is N-(4-Fluoro-phenyl)-6-(2-hydroxy-ethylamino)-1-oxy-nicotinamide.

20. (Withdrawn) A compound of claim 1 wherein said compound is 6-Bromo-N-(4-fluoro-phenyl)-1-oxy-nicotinamide.

21. (Withdrawn) A compound of claim 1 wherein said compound is 5,6-Dichloro-N-(4-fluoro-phenyl)-1-oxy-nicotinamide.

22. (Withdrawn) A compound of claim 1 wherein said compound is 6-Ethanesulfonyl-N-(4-fluoro-phenyl)-1-oxy-nicotinamide.

23. (Withdrawn) A compound of claim 1 wherein said compound is N-(4-Fluoro-phenyl)-1-oxy-6-(propane-2-sulfonyl)-nicotinamide.

24. (Withdrawn) A compound of claim 1 wherein said compound is N-(4-Fluoro-phenyl)-6-methanesulfonyl-1-oxy-nicotinamide.

25. (Withdrawn) A compound of claim 1 wherein said compound is 6-Benzenesulfonyl-N-(4-fluoro-phenyl)-1-oxy-nicotinamide.

26. (Withdrawn) A compound of claim 1 wherein said compound is N-(4-Fluoro-phenyl)-1-oxy-6-phenylmethanesulfonyl-nicotinamide.

27. (Withdrawn) A compound of claim 1 wherein said compound is 6-Chloro-N-(3-chloro-4-fluoro-phenyl)-1-oxy-nicotinamide.


28. (Withdrawn) A compound of claim 1 wherein said compound is 6-Chloro-N-(4-iodo-phenyl)-1-oxy-nicotinamide.

29. (Withdrawn) A compound of claim 1 wherein R^1 is selected from halogen, heteroalkyl or amino, R^2 is H, R^3 is aryl and R^4 is H.

30. (Withdrawn) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier, adjuvant or incipient.

31.-40 (Canceled)

41. (Currently Amended) A method for treating inflammation mediated at least in part by IL-8 or GRO- α , comprising administering to a patient in need thereof, through a therapeutically or prophylactically acceptable manner, a therapeutically or pharmaceutically effective amount of the a compound having the structure (I):



and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof, wherein

R^1 is selected from the group consisting of R^5 and R^5 -C₄-C₆-heteroalkylene)- R^5 -SO₂-, where R^5 is selected from the group consisting of hydrogen, halogen, alkyl, heteroalkyl, aryl, heteroaryl, ~~carbocycle-aliphatic ring and heterocycle-aliphatic ring~~, amino ~~[[or]]~~ and hydroxy; and

R^2 is hydrogen;

and R^3 ~~are independently hydrogen, alkyl, heteroalkyl, and,~~ is selected from the group consisting of aryl and aryl(alkylene), heteroaryl, heteroaryl(alkylene), carbocycle, carbocycle(alkylene), heterocycle, and heterocycle(alkylene).

42. (Original) The method of claim 41 wherein administration is selected from transdermal, oral, intravenous, intramuscular, vaginal, rectal, pulmonary, subcutaneous, sublingual and transmucosal administration.

43. (Withdrawn) A method for identifying a binding partner to a compound of claim 1 comprising:

immobilizing proteins known to be involved in the TNF- β signaling pathway onto a suitable carrier; and

passing a solution of said compounds in isolation or mixture over said proteins and analyzing for compound:protein complex formation using surface plasmon resonance (SPR).

44. (Withdrawn) A method for identifying a binding partner to a compound of claim 1 comprising:


providing said compound(s) bound to a solid support to provide solid phase compounds;

contacting a cell or cell components with said solid phase compounds in isolation or mixture;

removing uncomplexed cellular material, for example by gentle washing with aqueous buffer; and

recovering said binding partner from the solid phase compounds.

45. (Currently Amended) A method for antagonizing a chemokine receptor selected from the group consisting of: IL-8, and GRO- α , comprising administering to a patient in need thereof an effective amount of a compound having the structure (I):



and optical isomers, diastereomers, enantiomers and pharmaceutically acceptable salts thereof, wherein

R¹ is selected from the group consisting of R⁵ and R⁵-C₄-C₆-heteroalkylene)- R⁵-SO₂-, where R⁵ is selected from the group consisting of hydrogen, halogen, alkyl, heteroalkyl, aryl, heteroaryl, ~~carbocycle~~-aliphatic ring and ~~heterocycle~~-aliphatic ring, amino or and hydroxy; and

R² is hydrogen;

and R³ are independently ~~is~~ hydrogen; alkyl, heteroalkyl, aryl, is selected from the group consisting of aryl and aryl(alkylene), heteroaryl, heteroaryl(alkylene), carbocycle, carbocycle(alkylene), heterocycle, and heterocycle(alkylene).

46. (Cancelled)


47. (Currently Amended) The method of claim 45 wherein R^1 is R^5-SO_2 , and R^5 is selected from the group consisting of alkyl, heteroalkyl, and aryl, ~~carbocycle,~~ aryl(alkylene), ~~and carbocycle(alkylene).~~

48. (Currently Amended) The method of claim 47 wherein, for R^5 , alkyl is C_1-C_{10} alkyl; heteroalkyl is C_{10} alkyl with 1, 2 or 3 heteroatoms selected from N, O and S; and aryl is phenyl[[~~7~~]] or substituted phenyl, ~~naphthyl or substituted naphthyl;~~ ~~carbocycle is C_3-C_8 carbocycle;~~ ~~and alkylene is C_{10} alkyl.~~

49. (Canceled)

50. (Currently Amended) The method of claim 45 wherein $R^{[+]}{}^5$ is selected from the group consisting of halogen, amino, ~~hydrocarbylamino, dihydrocarbylamino,~~ hydrocarbyloxy, ~~hydrocarbylthio, heterocyclyl,~~ (heteroalkyl)amino, and (heteroaryl)amino.

51. (Currently Amended) The method of claim 49 50 wherein R^1 is selected from the group consisting of amino $(C_1-C_6alkyl)(C_1-C_6alkyl)amino$, $PhNH-$, $PhCH_2NH-$,




52. (Currently Amended) The method of claim 50 wherein R^1 is selected from a halide and $(C_1-C_6alkyl)S$ -halogen.

53. (Previously Presented) The method of claim 52 wherein R^1 is ~~chloride~~ chlorine.

54. (Canceled)

55. (Currently Amended) The method of claim ~~[[54]]~~ 45 wherein R^3 is aryl.

56. (Currently Amended) A method for antagonizing a chemokine receptor selected from the group consisting of: IL-8 and $GRO-\alpha$, comprising administering to a patient in need thereof an effective amount of a compound having the structure (II)



(II)

wherein R₁ is selected from the group consisting of (C₁₋₆alkyl)SO₂-, PhSO₂-, fluorinatedphenylSO₂-, PhCH₂SO₂-, cyclopentylSO₂-, *m*-carboxyphenylSO₂-, *m*-methylphenylSO₂-, and HOOC-(C₁-C₄alkylene)SO₂-.

57. (Canceled)

58. (Canceled)

59. (Canceled)